Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

Lebovitz, Harold E.; Kreider, Margaret; Freed, Martin I.
May 2002
Diabetes Care;May2002, Vol. 25 Issue 5, p815
Academic Journal
journal article
Objective: Troglitazone treatment has been associated with idiosyncratic hepatic reaction leading to hepatic failure and death in some patients. This raises questions regarding whether all thiazolidinediones or peroxisomal proliferator-activated receptor-gamma (PPAR-gamma) agonists are hepatotoxic and whether data from clinical trials are adequate to detect a signal of potentially serious drug-related hepatotoxicity. The purpose of this study was to assess whether the idiosyncratic liver toxicity reported with troglitazone is molecule-specific or a thiazolidinedione class effect, based on liver enzyme data collected prospectively during phase 2/3 clinical trials with rosiglitazone, a new, potent, and specific member of the thiazolidinedione class.Research Design and Methods: This is an analysis of liver function in type 2 diabetic patients at baseline and serially in 13 double-blind, 2 open-label active-controlled, and 7 open-label extension studies of rosiglitazone treatment conducted in outpatient centers throughout North America and Europe. The study comprised > 6,000 patients aged 30-80 years with type 2 diabetes. Patients underwent baseline liver function studies and were excluded from clinical trials if they had an alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase value 2.5 times greater than the upper limit of the reference range. The main outcome measures were liver enzyme levels, which were assessed at screening, at baseline, and every 4 weeks for the first 3 months of treatment and at 6- to 12-week intervals thereafter. Patients with at least one on-therapy ALT value >3 times the upper limit of the reference range were identified, and their case records examined in detail.Results: At baseline, 5.6% of the patients with type 2 diabetes (mean HbA(1c) 8.5-9.0%) had serum ALT values between 1.0 and 2.5 times the upper limit of the reference range. On antidiabetic therapy, most of those patients ( approximately 83%) had a decrease in ALT values, many into the normal range. The percentages of all patients with an on-therapy ALT value >3 times the upper limit of the reference range during double-blind and open-label treatment were as follows: rosiglitazone-treated 0.32%, placebo-treated 0.17%, and sulfonylurea-, metformin-, or insulin-treated 0.40%. The respective rates of ALT values >3 times the upper limit of the reference range per 100 person-years of exposure were 0.29, 0.59, and 0.64.Conclusions: No evidence of hepatotoxic effects was observed in studies that involved 5,006 patients taking rosiglitazone as monotherapy or combination therapy for 5,508 person-years. This is in keeping with hepatic data from clinical trials of another member of the class, pioglitazone, and in contrast to the clear evidence of hepatotoxic effects observed during the troglitazone clinical trial program. These findings suggest that the idiosyncratic liver toxicity observed with troglitazone is unlikely to be a thiazolidinedione or a PPAR-gamma agonist class effect. Poorly controlled patients with type 2 diabetes may have moderate elevations of serum ALT that will decrease with improved glycemic control during treatment with rosiglitazone or other antihyperglycemic agents.


Related Articles

  • Insulin resistance induced by high-fructose diet potentiates carbon tetrachloride hepatotoxicity. Pooranaperundevi, M.; Sumiyabanu, M. S.; Viswanathan, P.; Sundarapandiyan, R.; Anuradha, C. V. // Toxicology & Industrial Health;Mar2010, Vol. 26 Issue 2, p89 

    Insulin resistance (IR) is recognized as a contributory factor for a variety of liver diseases. The present study investigates the susceptibility of liver to the toxic actions of carbon tetrachloride (CCl4) in a rat model of IR, induced by feeding a high-fructose diet (60 g/100 g) for 30 days. A...

  • Molecular Modelling Analysis of the Metabolism of Troglitazone. Huq, Fazul // Asian Journal of Biochemistry;2007, Vol. 2 Issue 4, p256 

    In this study, molecular modelling analyses based on molecular mechanics, semi-empirical (PM3) and DFT (at B3LYP/6-31G* level)have been carried out for troglitazone (TGZ) and its metabolites with the aim of obtaining information on their relative toxicity. The results of the analyses show that...

  • Etiopathogenesis of Nonalcoholic Steatohepatitis: Role of Obesity, Insulin Resistance and Mechanisms of Hepatotoxicity. Guturu, Praveen; Duchini, Andrea // International Journal of Hepatology;2012, p1 

    Incidence of nonalcoholic fatty liver disease is increasing with an estimated prevalence of 20-30% in developed nations. This is leading to increased incidence of chronic liver disease, cirrhosis, and hepatocellular cancer. It is critical to understand the etiology and pathogenesis of any...

  • Resisting insulin resistance.  // Consumer Reports on Health;Jun98, Vol. 10 Issue 6, p6 

    Presents information from a study on insulin resistance which was conducted by researchers at the United States Sports Academy in Daphne, Alabama. What is insulin resistance; What previous research on insulin resistance suggested; Results of the study.

  • Understanding insulin resistance and syndrome X. Garber, Alan J.; Gavin III, James R. // Patient Care;6/15/1996, Vol. 30 Issue 11, p198 

    Discusses insulin resistance in diabetic patients. Syndromes of insulin resistance; Treatment approaches; Consequences and complications. INSETS: The diabetes prevention program.;The patient with diabetes..

  • Erratum.  // Journal of Clinical Investigation;Mar2010, Vol. 120 Issue 3, p932 

    A correction to the article "Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure" is presented.

  • Management of syndrome X.  // American Family Physician;1/1/1997, Vol. 55 Issue 1, p341 

    Presents an abstract of an article in the November 1996 issue of the periodical `Canadian Family Physician,' that focused on the management of the insulin resistant condition called syndrome X. Manifestation of the disease; Factor attributed to the spread of syndrome X.

  • Voriconazole.  // Reactions Weekly;7/23/2011, Issue 1361, p41 

    The article describes the case of a lung transplant recipient who developed voriconazole-induced hepatotoxicity, published in the June 2011 issue of "Transplant Infectious Disease."

  • Correction: Gatifloxacin-Induced Hepatotoxicity and Acute Pancreatitis.  // Annals of Internal Medicine;2/17/2004, Vol. 140 Issue 4, p315 

    Presents a correction of an author affiliation in the case reported on gatifloxacin-induced hepatotoxicity and acute pancreatitis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics